ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG

(EUZ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Eckert & Ziegler Strahlen und Medizintechnik : & Ziegler and Telix Pharmaceuticals Enter Co-Promotion Agreement for Prostate Cancer Diagnostic in the United States

06/03/2021 | 02:09am EDT

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Alliance
Eckert & Ziegler and Telix Pharmaceuticals Enter Co-Promotion Agreement for Prostate Cancer Diagnostic in the United States

03.06.2021 / 08:07
The issuer is solely responsible for the content of this announcement.


Berlin, 3 June 2021. Eckert & Ziegler (ISIN DE0005659700, TecDAX) and Telix Pharmaceuticals (Telix) will cooperate closely in the commercialization of GalliaPharm(R) (68Ge/68Ga Generator) and investigational product Illuccix(R) (Kit for the preparation of Ga-68 PSMA-11 injection) in the United States. An agreement to this effect has now been signed by the two companies. Illuccix(R) is a preparation for imaging prostate cancer by positron emission tomography (PET) and is currently under review for regulatory approval in the United States and multiple markets worldwide.

Eckert & Ziegler and Telix will expand their existing collaboration to further develop access to Ga-68 supply in the United States. The parties will both promote the combination of GalliaPharm(R) and Illuccix(R) to national radiopharmacy networks, commercial and hospital-based nuclear pharmacies, and other target institutions.

"After previously being granted distribution rights for Germany, our home market, the latest collaboration marks another important milestone for our 68Ga generator GalliaPharm(R) and our nuclear medicine activities", explained Dr Harald Hasselmann, Eckert & Ziegler Executive Director and responsible for the Medical segment. "We are pleased to have Telix as a partner and to be able to jointly provide leading edge diagnostic products to prostate cancer patients in the USA."

"This important cooperation between EZAG and Telix sales teams is highly complementary to our efforts in rolling out 68Ga-PSMA imaging across the US. Subject to FDA approval, we will together raise awareness of this state-of-the-art imaging modality and facilitate coast-to-coast access for US men living with prostate cancer.", added Telix Americas President Dr Bernard Lambert.

Following regulatory approval, Illuccix(R) will be offered as a cold kit preparation for the diagnosis of prostate cancer. For this purpose, Illuccix(R) enables PSMA-11 to be radio-labelled with the radionuclide 68Ga directly before injection by medical personnel. After preparing the radiopharmaceutical and injecting it into the patient, sites exhibiting prostate cancer are localized and imaged via the presence of the prostate-specific membrane antigen.[1],[2]

Prostate cancer is the most common type of cancer in men in the United States, with approximately 210,000 cases in 2020, a significantly higher incidence than either lung cancer (116,000 new cases) or bowel cancer (82,000 new cases).[3] Prostate cancer was also the second most common cause of cancer death in men, with over 32,000 men dying from the disease in the United States in 2020. More than 812,000 American men were estimated to be living with prostate cancer in 2020.

[1] Fendler W et al. JAMA Oncol. 2019; 5(6): 856-863.
[2] Hofman M et al. The Lancet. 2020; 395: 1208-1216.
[3] IARC Global Cancer Observatory, 2020.

About Eckert & Ziegler
Eckert & Ziegler Strahlen- und Medizintechnik AG with around 800 employees, is one of the world's largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at its worldwide locations, from early development to commercialization. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

About Telix Pharmaceuticals
Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.

About Illuccix(R)
Telix's lead investigational product, Illuccix(R) (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA, and is under priority evaluation by the Australian Therapeutic Goods Administration (TGA). Telix is also progressing marketing authorisation applications for Illuccix(R) in the European Union and Canada. None of Telix's products have received a marketing authorisation in any jurisdiction.

Eckert & Ziegler AG Contact:
Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com

Telix Pharmaceuticals Contact:
Dr. Stewart Holmstrom, Investor Relations
Suite 401, 55 Flemington Road, North Melbourne, VIC 3051, Australia
Email: stewart.holmstrom@telixpharma.com



03.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1203887

 
End of News DGAP News Service

1203887  03.06.2021 

fncls.ssp?fn=show_t_gif&application_id=1203887&application_name=news&site_id=zonebourse_sftp

© EQS 2021
All news about ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
05/12Eckert & Ziegler Strahlen- und Medizintechnik AG Reports Earnings Results for the First..
CI
05/12Eckert & Ziegler with Sales Growth in the First Quarter of 2022
EQ
05/12Eckert & Ziegler Strahlen- und Medizintechnik AG Reaffirms Earnings Guidance for the Ye..
CI
05/11Eckert & Ziegler Cooperates with Czech Research Center UJF to Produce Pharmaceutical Al..
EQ
05/11Eckert & Ziegler Cooperates with Czech Research Center UJF to Produce Pharmaceutical Al..
CI
04/12ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Report of the Supervisory Board
PU
04/12ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Proposal on the appropriation of net income
PU
04/11ECKERT & ZIEGLER : Hauck & Aufhauser remains its Buy rating
MD
04/11ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Hauck & Aufhäuser
PU
04/08ECKERT & ZIEGLER : Radboud University Medical Center Netherlands to Image First Patient wi..
EQ
More news
Analyst Recommendations on ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
More recommendations
Financials
Sales 2022 205 M 216 M 216 M
Net income 2022 30,7 M 32,3 M 32,3 M
Net cash 2022 55,7 M 58,7 M 58,7 M
P/E ratio 2022 28,8x
Yield 2022 1,17%
Capitalization 890 M 938 M 938 M
EV / Sales 2022 4,07x
EV / Sales 2023 3,91x
Nbr of Employees 866
Free-Float 67,1%
Chart ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
Duration : Period :
Eckert & Ziegler Strahlen- und Medizintechnik AG Technical Analysis Chart | EUZ | DE0005659700 | MarketScreener
Technical analysis trends ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 42,90 €
Average target price 152,00 €
Spread / Average Target 254%
EPS Revisions
Managers and Directors
Andreas Eckert Chairman-Executive Board
Wolfgang Maennig Chairman-Supervisory Board
Helmut Grothe Vice Chairman-Supervisory Board
Albert Rupprecht Member-Supervisory Board
Edgar Löffler Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG-54.41%938
JOHNSON & JOHNSON4.53%470 547
PFIZER, INC.-13.06%288 063
ABBVIE INC.14.31%273 513
ELI LILLY AND COMPANY9.12%271 308
ROCHE HOLDING AG-14.97%263 868